Navigation Links
ViroPharma to Release 2009 Third Quarter Financial Results on October 28, 2009
Date:10/15/2009

EXTON, Pa., Oct. 15 /PRNewswire-FirstCall/ -- ViroPharma Incorporated's (Nasdaq: VPHM) third quarter financial results for 2009 are expected to be released on Wednesday, October 28, 2009 before the open of the U.S. financial markets.

The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day. During the conference call, ViroPharma management will discuss the 2009 third quarter and other business.

The press release and the live webcast of the conference call will be accessible via ViroPharma's corporate website at http://www.viropharma.com. An audio archive will be available at the same address until November 21, 2009. To participate in the conference call, please dial (888) 299-4099 (domestic) and (302) 709-8337 (international). After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. ViroPharma commercializes Cinryze(TM) (C1 esterase inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. ViroPharma Announces Initiation Of Non-Toxigenic Clostridium Difficile Phase 1 Program
2. ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomycin Hydorchloride
3. ViroPharma Incorporated Reports Second Quarter 2009 Financial Results
4. ViroPharma to Release 2009 Second Quarter Financial Results on July 29, 2009
5. ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors
6. ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products
7. ViroPharma to Present at Two May Healthcare Conferences
8. ViroPharma to Present at the Cowen & Company 29th Annual Healthcare Conference
9. ViroPharma to Host Investor Teach-In Educational Symposium on Hereditary Angioedema
10. ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
11. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... finalist in 2015 MarketingProfs Bright Bulb B2B Awards. , The MarketingProfs Bright Bulb ... for B2B brands. BESLER Consulting's campaign for the launch of their Readmissions Analytics ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today welcomed ... accepted for review OPKO’s New Drug Application for a new treatment for chronic ...
(Date:8/3/2015)... ... ... The art of preparing and cooking food comes naturally to some. For ... Nasreen Zereshki was extremely eager to cook Persian cuisine. Now that she is skilled ... Kitchen with the world. , Since Americans tend to be undereducated about Persian cuisine, ...
(Date:8/3/2015)... ... ... The U.S. Food and Drug Administration (FDA) recently approved a new non-invasive treatment ... naturally in the body and helps absorb and breakdown fat cells. Previously, plastic surgery ... are invasive procedures and very expensive for most people. Now with Kybella, there is ...
(Date:8/3/2015)... ... ... Dignity Health named Dr. Norris A. Baldwin, Jr. the Facility Medical Director ... August. The new facility is licensed under Dignity Health Arizona General Hospital ... is an excellent leader and will ensure our new freestanding emergency room delivers the ...
Breaking Medicine News(10 mins):Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Persian Cuisine: Colorful and Extremely Healthy 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3
... drivers suspected of driving while ‘over the limit,’ but subsequently ... tested positive// for a range of drugs, reveals research in ... call for routine drugs testing in all drivers who are ... ,The researchers base their findings on 2000 blood and urine ...
... the open access journal BMC Medicine has found that the ... in India are flawed and the actual number of cases ... are from the Administrative Staff College of India, conducted the ... Medical Sciences in Hyderabad. ,According to the ...
... of his family served in the Indian Army and battled the ... Sena Medal winner// and with ‘Showrya’ meaning ‘brave’ for a name, ... family path. ,But a fall from the first floor ... the one-and-a-half-year-old Showrya Malik, who was pronounced ‘brain dead’ the next ...
... Pradesh government is considering setting up a medical and health ... Health Minister Ajay Vishnoi said Tuesday. ,"The government ... Medical Council of India for opening the university," Vishnoi told ... workshop on Indian medical systems. ,"The need ...
... are not protected from attacks or stroke by taking a ... ,Folic acid or folate is one of the B Vitamins ... medical practitioners prescribe it to prevent cardiac problems. ... Health and Tropical Medicine, New Orleans led a research on ...
... damaging to health, but obesity has higher damaging properties, ... cancers reducing a person’s life span by seven years ... ,Ken Snider, advisor at NICE i.e. National Institute for ... not only to do with weight loss but also ...
Cached Medicine News:Health News:One in Three Drivers Under ‘The Limit’ for Alcohol Still Test Positive for Dru 2Health News:A ‘Brave’ Toddler-The Youngest Organ Don 2Health News:Ways to Fight Childhood Obesity 2
(Date:8/3/2015)... 3, 2015  CytomX, a biopharmaceutical company developing ... announced the promotion of several members of its ... who previously served as vice president of business ... senior vice president of corporate development and strategy. ... as the vice president of business development at ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 ... its primary and secondary endpoints in a phase III ... (OIC) in adult patients with chronic non-cancer pain. Naldemedine ... (PAMORA). This is the third Phase III trial in ... Study results showed that a 0.2 mg ...
(Date:8/3/2015)... -- Encision Inc. (PK:ECIA), a medical device company owning patented ... minimally invasive surgery, today announced financial results for its ... The Company posted quarterly net revenue of ... thousand, or $(0.02) per share. These results compare to ... of $202 thousand, or $(0.02) per share, in the ...
Breaking Medicine Technology:CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
... statement by Michael J. Sullivan, Pharmaceutical Industry Labor-Management Association Chair: ... to advance a national  innovation agenda, one that stands to ... part: what can the administration and  Members of Congress specifically ... quality of life for working Americans? The President did a ...
... -- American Oriental Bioengineering, Inc. (NYSE: ... company dedicated to improving healthcare through the development, ... prescription and over-the-counter ("OTC") products, today announced that ... Liu and Chief Financial Officer, Ms. Lily Li ...
Cached Medicine Technology:American Oriental Bioengineering's CEO and CFO Visit the United States as Entrepreneur Representatives of President Hu Jintao's Delegation 2
... Vitrectomy Lenses are a family of single-use direct ... of a particular region of the retinal surface ... less than 1 gram and is formed and ... of a human cornea. Lenses come in boxes ...
... The AFX Lens is a ... use in an air-filled eye. ... as a primary air-fluid exchange ... and sutureless design make it ...
... The Chalam 30° Prism are ... and are recommended for tractional ... and Rhegmatogenus retinal detachment. They ... photocoagulation and other midperipheral laser ...
... 45° Prism is designed ... and are recommended for ... BRVO etc.) and Rhegmatogenus ... be used for panretinal ...
Medicine Products: